The Use of New CRISPR Tools in Cardiovascular Research and Medicine

Overview

Journal Nat Rev Cardiol

Specialty Cardiology & Vascular Diseases

Date 2022 Feb 11

PMID 35145236

Authors

Masataka Nishiga

Chun Liu

Lei S Qi

Joseph C Wu

Affiliations

Soon will be listed here.

Abstract

Many novel CRISPR-based genome-editing tools, with a wide variety of applications, have been developed in the past few years. The original CRISPR-Cas9 system was developed as a tool to alter genomic sequences in living organisms in a simple way. However, the functions of new CRISPR tools are not limited to conventional genome editing mediated by non-homologous end-joining or homology-directed repair but expand into gene-expression control, epigenome editing, single-nucleotide editing, RNA editing and live-cell imaging. Furthermore, genetic perturbation screening by multiplexing guide RNAs is gaining popularity as a method to identify causative genes and pathways in an unbiased manner. New CRISPR tools can also be applied to ex vivo or in vivo therapeutic genome editing for the treatment of conditions such as hyperlipidaemia. In this Review, we first provide an overview of the diverse new CRISPR tools that have been developed to date. Second, we summarize how these new CRISPR tools are being used to study biological processes and disease mechanisms in cardiovascular research and medicine. Finally, we discuss the prospect of therapeutic genome editing by CRISPR tools to cure genetic cardiovascular diseases.

Citing Articles

CRISPR-Cas9 in Cardiovascular Medicine: Unlocking New Potential for Treatment.

Bonowicz K, Jerka D, Piekarska K, Olagbaju J, Stapleton L, Shobowale M Cells. 2025; 14(2).

PMID: 39851560 PMC: 11763404. DOI: 10.3390/cells14020131.

CRISPRi/a screens in human iPSC-cardiomyocytes identify glycolytic activation as a druggable target for doxorubicin-induced cardiotoxicity.

Liu C, Shen M, Liu Y, Manhas A, Zhao S, Zhang M Cell Stem Cell. 2024; 31(12):1760-1776.e9.

PMID: 39515331 PMC: 11646563. DOI: 10.1016/j.stem.2024.10.007.

BES-Designer: A Web Tool to Design Guide RNAs for Base Editing to Simplify Library.

Zhou Q, Gao Q, Gao Y, Zhang Y, Chen Y, Li M Interdiscip Sci. 2024; 17(1):134-139.

PMID: 39466357 DOI: 10.1007/s12539-024-00663-6.

Gene therapy for atrial fibrillation.

Mo W, Donahue J J Mol Cell Cardiol. 2024; 196:84-93.

PMID: 39270930 PMC: 11534567. DOI: 10.1016/j.yjmcc.2024.09.004.

Precision Genetic Therapies: Balancing Risk and Benefit in Patients with Heart Failure.

Johnston J, Adler E Curr Cardiol Rep. 2024; 26(9):973-983.

PMID: 39110386 PMC: 11379760. DOI: 10.1007/s11886-024-02096-5.

References

Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View

Ding Q, Strong A, Patel K, Ng S, Gosis B, Regan S . Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. 2014; 115(5):488-92. PMC: 4134749. DOI: 10.1161/CIRCRESAHA.115.304351. View

Kannan S, Altae-Tran H, Jin X, Madigan V, Oshiro R, Makarova K . Compact RNA editors with small Cas13 proteins. Nat Biotechnol. 2021; 40(2):194-197. PMC: 8929162. DOI: 10.1038/s41587-021-01030-2. View

Perez-Pinera P, Kocak D, Vockley C, Adler A, Kabadi A, Polstein L . RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods. 2013; 10(10):973-6. PMC: 3911785. DOI: 10.1038/nmeth.2600. View

Chen Y, Zheng Y, Kang Y, Yang W, Niu Y, Guo X . Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9. Hum Mol Genet. 2015; 24(13):3764-74. PMC: 5007610. DOI: 10.1093/hmg/ddv120. View

Maeder M, Linder S, Cascio V, Fu Y, Ho Q, Joung J . CRISPR RNA-guided activation of endogenous human genes. Nat Methods. 2013; 10(10):977-9. PMC: 3794058. DOI: 10.1038/nmeth.2598. View

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

Nelson C, Wu Y, Gemberling M, Oliver M, Waller M, Bohning J . Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med. 2019; 25(3):427-432. PMC: 6455975. DOI: 10.1038/s41591-019-0344-3. View

Wright A, Nunez J, Doudna J . Biology and Applications of CRISPR Systems: Harnessing Nature's Toolbox for Genome Engineering. Cell. 2016; 164(1-2):29-44. DOI: 10.1016/j.cell.2015.12.035. View

10.

Fairclough R, Wood M, Davies K . Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet. 2013; 14(6):373-8. DOI: 10.1038/nrg3460. View

11.

Zeng Y, Li J, Li G, Huang S, Yu W, Zhang Y . Correction of the Marfan Syndrome Pathogenic FBN1 Mutation by Base Editing in Human Cells and Heterozygous Embryos. Mol Ther. 2018; 26(11):2631-2637. PMC: 6224777. DOI: 10.1016/j.ymthe.2018.08.007. View

12.

Chavez A, Scheiman J, Vora S, Pruitt B, Tuttle M, Iyer E . Highly efficient Cas9-mediated transcriptional programming. Nat Methods. 2015; 12(4):326-8. PMC: 4393883. DOI: 10.1038/nmeth.3312. View

13.

Ran F, Cong L, Yan W, Scott D, Gootenberg J, Kriz A . In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015; 520(7546):186-91. PMC: 4393360. DOI: 10.1038/nature14299. View

14.

Pierce S, Granja J, Greenleaf W . High-throughput single-cell chromatin accessibility CRISPR screens enable unbiased identification of regulatory networks in cancer. Nat Commun. 2021; 12(1):2969. PMC: 8137922. DOI: 10.1038/s41467-021-23213-w. View

15.

Datlinger P, Rendeiro A, Schmidl C, Krausgruber T, Traxler P, Klughammer J . Pooled CRISPR screening with single-cell transcriptome readout. Nat Methods. 2017; 14(3):297-301. PMC: 5334791. DOI: 10.1038/nmeth.4177. View

16.

Komor A, Kim Y, Packer M, Zuris J, Liu D . Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016; 533(7603):420-4. PMC: 4873371. DOI: 10.1038/nature17946. View

17.

Zsebo K, Yaroshinsky A, Rudy J, Wagner K, Greenberg B, Jessup M . Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res. 2013; 114(1):101-8. DOI: 10.1161/CIRCRESAHA.113.302421. View

18.

Stolze L, Conklin A, Whalen M, Lopez Rodriguez M, Ounap K, Selvarajan I . Systems Genetics in Human Endothelial Cells Identifies Non-coding Variants Modifying Enhancers, Expression, and Complex Disease Traits. Am J Hum Genet. 2020; 106(6):748-763. PMC: 7273528. DOI: 10.1016/j.ajhg.2020.04.008. View

19.

Marraffini L . CRISPR-Cas immunity in prokaryotes. Nature. 2015; 526(7571):55-61. DOI: 10.1038/nature15386. View

20.

Chadwick A, Wang X, Musunuru K . In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing. Arterioscler Thromb Vasc Biol. 2017; 37(9):1741-1747. PMC: 5570639. DOI: 10.1161/ATVBAHA.117.309881. View